Search results for "RIP"

showing 10 items of 9780 documents

Soluble Platelet Release Factors as Biomarkers for Cardiovascular Disease

2021

Platelets are the main players in thrombotic diseases, where activated platelets not only mediate thrombus formation but also are involved in multiple interactions with vascular cells, inflammatory components, and the coagulation system. Although in vitro reactivity of platelets provides information on the function of circulating platelets, it is not a full reflection of the in vivo activation state, which may be relevant for thrombotic risk assessment in various disease conditions. Therefore, studying release markers of activated platelets in plasma is of interest. While this type of study has been done for decades, there are several new discoveries that highlight the need for a critical a…

0301 basic medicineACUTE MYOCARDIAL-INFARCTIONVON-WILLEBRAND-FACTORDEEP VENOUS THROMBOSISvenous thromboembolismCD40 LIGANDContext (language use)ReviewDiseaseCardiovascular Medicinearterial thrombosis030204 cardiovascular system & hematologyBioinformatics03 medical and health sciences0302 clinical medicineVon Willebrand factorPERIPHERAL ARTERY-DISEASENONVALVULAR ATRIAL-FIBRILLATIONmedicineDiseases of the circulatory (Cardiovascular) systematrial fibrillationPlateletACUTE ISCHEMIC-STROKEMyocardial infarctionPlatelet activationThrombusthrombosisbiologybusiness.industryACUTE CORONARY SYNDROMESbiomarkersmedicine.diseaseThrombosisC-REACTIVE PROTEIN3. Good healthP-SELECTIN LEVELS030104 developmental biologyRC666-701plateletsbiology.proteinCardiology and Cardiovascular MedicinebusinessFrontiers in Cardiovascular Medicine
researchProduct

Epimagnolin A, a tetrahydrofurofuranoid lignan from Magnolia fargesii, reverses ABCB1-mediated drug resistance.

2018

Abstract Background Epimagnolin A is an ingredient of the Chinese crude drug Shin-i, derived from the dried flower buds of Magnolia fargesii and Magnolia flos, which has been traditionally used for the treatment of allergic rhinitis and nasal congestion, empyema, and sinusitis. The pharmacokinetic activity of epimagnolin A remains to be evaluated. Purpose In this study, we examined the possible interactions of epimagnolin A with human ATP-binding cassette (ABC) transporter ABCB1, a membrane protein vital in regulating the pharmacokinetics of drugs and xenobiotics. Study design/methods The interaction of epimagnolin A with ABCB1 was evaluated in calcein, ATPase, and MTT assays by using Flp-I…

0301 basic medicineATP Binding Cassette Transporter Subfamily BATPasePharmaceutical ScienceATP-binding cassette transporterPharmacologyCrude drugLignans03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePharmacokineticsCell Line TumorDrug DiscoverymedicineHumansEnzyme kineticsP-glycoproteinPharmacologyAdenosine TriphosphatasesbiologyAntineoplastic Agents PhytogenicDrug Resistance MultipleCalceinMolecular Docking Simulation030104 developmental biologyComplementary and alternative medicinechemistryVerapamilDrug Resistance NeoplasmMagnolia030220 oncology & carcinogenesisbiology.proteinMolecular MedicineVerapamilmedicine.drugPhytomedicine : international journal of phytotherapy and phytopharmacology
researchProduct

Genomic and transcriptomic profiling of resistant CEM/ADR-5000 and sensitive CCRF-CEM leukaemia cells for unravelling the full complexity of multi-fa…

2016

AbstractWe systematically characterised multifactorial multidrug resistance (MDR) in CEM/ADR5000 cells, a doxorubicin-resistant sub-line derived from drug-sensitive, parental CCRF-CEM cells developed in vitro. RNA sequencing and network analyses (Ingenuity Pathway Analysis) were performed. Chromosomal aberrations were identified by array-comparative genomic hybridisation (aCGH) and multicolour fluorescence in situ hybridisation (mFISH). Fifteen ATP-binding cassette transporters and numerous new genes were overexpressed in CEM/ADR5000 cells. The basic karyotype in CCRF-CEM cells consisted of 47, XX, der(5)t(5;14) (q35.33;q32.3), del(9) (p14.1), +20. CEM/ADR5000 cells acquired additional aber…

0301 basic medicineATP Binding Cassette Transporter Subfamily BDNA RepairDown-RegulationChromosomal translocationABCC5ArticleTranslocation GeneticTranscriptome03 medical and health sciences0302 clinical medicineATP Binding Cassette Transporter Subfamily G Member 2HumansGeneIn Situ Hybridization FluorescenceChromosome 7 (human)GeneticsComparative Genomic HybridizationGenomeLeukemiaMultidisciplinarybiologySequence Analysis RNAGene Expression ProfilingGenomicsNeoplasm ProteinsMultiple drug resistanceGene expression profiling030104 developmental biologyDrug Resistance Neoplasm030220 oncology & carcinogenesisbiology.proteinTranscriptomeComparative genomic hybridizationScientific Reports
researchProduct

Repurposing of Bromocriptine for Cancer Therapy

2018

Bromocriptine is an ergot alkaloid and dopamine D2 receptor agonist used to treat Parkinson’s disease, acromegaly, hyperprolactinemia, and galactorrhea, and more recently diabetes mellitus. The drug is also active against pituitary hormone-dependent tumors (prolactinomas and growth-hormone producing adenomas). We investigated, whether bromocriptine also inhibits hormone-independent and multidrug-resistant (MDR) tumors. We found that bromocriptine was cytotoxic towards drug-sensitive CCRF-CEM, multidrug-resistant CEM/ADR5000 leukemic cells as well as wild-type or multidrug-resistant ABCB5-transfected HEK293 cell lines, but not sensitive or BCRP-transfected multidrug-resistant MDA-MB-231 brea…

0301 basic medicineAbcg2DNA damageDNA repairCellneoplasmsergot alkaloids03 medical and health sciencesDopamine receptor D2AcromegalymedicinePharmacology (medical)Original ResearchbromocriptinepharmacogenomicsPharmacologydrug repurposingbiologybusiness.industrylcsh:RM1-950medicine.diseaseBromocriptinelcsh:Therapeutics. Pharmacology030104 developmental biologymedicine.anatomical_structureMitochondrial respiratory chainCancer researchbiology.proteinbusinessmedicine.drugFrontiers in Pharmacology
researchProduct

Multifactorial Modes of Action of Arsenic Trioxide in Cancer Cells as Analyzed by Classical and Network Pharmacology

2018

Arsenic trioxide is a traditional remedy in Chinese Medicine since ages. Nowadays, it is clinically used to treat acute promyelocytic leukemia (APL) by targeting PML/RARA. However, the drug’s activity is broader and the mechanisms of action in other tumor types remain unclear. In this study, we investigated molecular modes of action by classical and network pharmacological approaches. CEM/ADR5000 resistance leukemic cells were similar sensitive to As2O3 as their wild-type counterpart CCRF-CEM (resistance ratio: 1.88). Drug-resistant U87.MG ΔEGFR glioblastoma cells harboring mutated epidermal growth factor receptor were even more sensitive (collateral sensitive) than wild-type U87.MG cells (…

0301 basic medicineAcute promyelocytic leukemiaBiologyNF-κB03 medical and health scienceschemistry.chemical_compound0302 clinical medicinemedicinePharmacology (medical)Epidermal growth factor receptorArsenic trioxideTranscription factorOriginal ResearchpharmacogenomicsPharmacologydrug resistancelcsh:RM1-950PromoterAP-1medicine.diseasearsenic trioxidelcsh:Therapeutics. Pharmacology030104 developmental biologychemistryCistromeCell culture030220 oncology & carcinogenesisCancer cellCancer researchbiology.proteinFrontiers in Pharmacology
researchProduct

Retinoic Acid affects Lung Adenocarcinoma growth by inducing differentiation via GATA6 activation and EGFR and Wnt inhibition

2016

AbstractA fundamental task in cancer research aims at the identification of new pharmacological therapies that can affect tumor growth. Differentiation therapy might exploit this function not only for hematological diseases, such as acute promyelocytic leukemia (APML) but also for epithelial tumors, including lung cancer. Here we show that Retinoic Acid (RA) arrests in vitro and in vivo the growth of Tyrosine Kinase Inhibitors (TKI) resistant Non Small Cell Lung Cancer (NSCLC). In particular, we found that RA induces G0/G1 cell cycle arrest in TKI resistant NSCLC cells and activates terminal differentiation programs by modulating the expression of GATA6, a key transcription factor involved …

0301 basic medicineAcute promyelocytic leukemiaScienceEGFRRetinoic acidMice NudeTretinoinBiologyArticle03 medical and health scienceschemistry.chemical_compoundDifferentiation therapySettore BIO/13 - Biologia ApplicataCarcinoma Non-Small-Cell LungCell Line TumorGATA6 Transcription FactormedicineRetinoic acidAnimalsHumansLung cancerProtein Kinase InhibitorsWnt Signaling PathwayTranscription factorCell ProliferationMultidisciplinaryQRWnt signaling pathwayCell Differentiationmedicine.diseaseG1 Phase Cell Cycle CheckpointsXenograft Model Antitumor Assaysrespiratory tract diseasesErbB Receptorslung cancerAnimals; Carcinoma Non-Small-Cell Lung; Cell Differentiation; Cell Line Tumor; Cell Proliferation; Drug Resistance Neoplasm; ErbB Receptors; G1 Phase Cell Cycle Checkpoints; GATA6 Transcription Factor; Humans; Mice Nude; Protein Kinase Inhibitors; Signal Transduction; Tretinoin; Wnt Signaling Pathway; Xenograft Model Antitumor Assays030104 developmental biologychemistryDrug Resistance NeoplasmImmunologyCancer researchMedicineAdenocarcinomaEngineering sciences. TechnologyTyrosine kinaseSignal Transduction
researchProduct

Assessment of tumor-infiltrating TCRV γ 9V δ 2 γδ lymphocyte abundance by deconvolution of human cancers microarrays

2017

Most human blood γδ cells are cytolytic TCRVγ9Vδ2+lymphocytes with antitumor activity. They are currently investigated in several clinical trials of cancer immunotherapy but so far, their tumor infiltration has not been systematically explored across human cancers. Novel algorithms allowing the deconvolution of bulk tumor transcriptomes to find the relative proportions of infiltrating leucocytes, such as CIBERSORT, should be appropriate for this aim but in practice they fail to accurately recognize γδ T lymphocytes. Here, by implementing machine learning from microarray data, we first improved the computational identification of blood-derived TCRVγ9Vδ2+γδ lymphocytes and then appl…

0301 basic medicineAcute promyelocytic leukemia[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematologylcsh:Immunologic diseases. AllergyArtificial intelligenceMicroarrayLymphocytemedicine.medical_treatmentImmunologyInflammationchemical and pharmacologic phenomenagamma delta lymphocyteBiologydeconvolutionlcsh:RC254-28203 medical and health sciences0302 clinical medicineCancer immunotherapymedicineImmunology and AllergycancerOriginal ResearchTumor-infiltrating lymphocytesAntigen processingMyeloid leukemiahemic and immune systems[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematologydata miningmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good health030104 developmental biologymedicine.anatomical_structuremachine learningOncology030220 oncology & carcinogenesisImmunologymedicine.symptomlcsh:RC581-607microarraytranscriptome
researchProduct

High-throughput sequencing for 1-methyladenosine (m1A) mapping in RNA

2016

Abstract Detection and mapping of modified nucleotides in RNAs is a difficult and laborious task. Several physico-chemical approaches based on differential properties of modified nucleotides can be used, however, most of these methods do not allow high-throughput analysis. Here we describe in details a method for mapping of rather common 1-methyladenosine (m1A) residues using high-throughput next generation sequencing (NGS). Since m1A residues block primer extension during reverse transcription (RT), the accumulation of abortive products as well as the nucleotide misincorporation can be detected in the sequencing data. The described library preparation protocol allows to capture both types …

0301 basic medicineAdenosineLibrary preparationSequencing dataBiologyGeneral Biochemistry Genetics and Molecular BiologyDNA sequencingPrimer extension03 medical and health sciencesComplementary DNANucleotideRNA Processing Post-Transcriptional[SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry Molecular Biology/Biochemistry [q-bio.BM]Molecular BiologyComputingMilieux_MISCELLANEOUSGene LibraryGeneticschemistry.chemical_classificationRNAHigh-Throughput Nucleotide Sequencing[SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biologyReverse transcriptase030104 developmental biologychemistryRNA[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Engineering of a DNA Polymerase for Direct m6A Sequencing

2017

Methods for the detection of RNA modifications are of fundamental importance for advancing epitranscriptomics. N6-methyladenosine (m6A) is the most abundant RNA modification in mammalian mRNA and is involved in the regulation of gene expression. Current detection techniques are laborious and rely on antibody-based enrichment of m6A-containing RNA prior to sequencing, since m6A modifications are generally "erased" during reverse transcription (RT). To overcome the drawbacks associated with indirect detection, we aimed to generate novel DNA polymerase variants for direct m6A sequencing. Therefore, we developed a screen to evolve an RT-active KlenTaq DNA polymerase variant that sets a mark for…

0301 basic medicineAdenosineRNA-dependent RNA polymeraseDNA-Directed DNA Polymerase010402 general chemistryProtein Engineering01 natural sciencesCatalysis03 medical and health sciencesDNA polymerasesSequencing by hybridization[SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN]TheoryofComputation_ANALYSISOFALGORITHMSANDPROBLEMCOMPLEXITYRNA polymerase IRNA MessengerPolymerasebiologyOligonucleotideN6-methyladenosineReverse Transcriptase Polymerase Chain ReactionCommunicationMultiple displacement amplificationHigh-Throughput Nucleotide Sequencing[SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biologyGeneral ChemistryDNA MethylationRNA modificationMolecular biologyReverse transcriptaseCommunications0104 chemical sciencesSequencing by ligationenzyme engineering030104 developmental biologyComputingMethodologies_PATTERNRECOGNITIONddc:540biology.proteinepitranscriptomicsRNA Methylation
researchProduct

Polyphosphate as a donor of high-energy phosphate for the synthesis of ADP and ATP.

2017

Here, we studied the potential role of inorganic polyphosphate (polyP) as an energy source for ADP and ATP formation in the extracellular space. In SaOS-2 cells, we show that matrix vesicles are released into the extracellular space after incubation with polyP. These vesicles contain both alkaline phosphatase (ALP) and adenylate kinase (AK) activities (mediated by ALPL and AK1 enzymes). Both enzymes translocate to the cell membrane in response to polyP. To distinguish the process(es) of AMP and ADP formation during ALP hydrolysis from the ATP generated via the AK reaction, inhibition studies with the AK inhibitor A(5')P5(5')A were performed. We found that ADP formation in the extracellular …

0301 basic medicineAdenylate kinaseBiologydigestive systemExocytosisCatalysisCell membrane03 medical and health scienceschemistry.chemical_compound0302 clinical medicineAdenosine TriphosphatePolyphosphatesExtracellularmedicineTumor Cells CulturedHumansPhosphorylationchemistry.chemical_classificationATP synthasePolyphosphateAdenylate KinaseCell BiologyAlkaline PhosphataseAdenosine DiphosphateKinetics030104 developmental biologyEnzymemedicine.anatomical_structurechemistryBiochemistry030220 oncology & carcinogenesisbiology.proteinEnergy sourceEnergy MetabolismExtracellular SpaceJournal of cell science
researchProduct